Swift Transportation donates more than $15,000 to the Waylon Fund

December 13, 2012

PHOENIX, Ariz. -- Dec. 13, 2012 -- Swift Charities, the charitable arm of Swift Transportation, today donated $15,262 to The Waylon Jennings Fund for Diabetes Research at the Translational Genomics Research Institute (TGen).

Throughout November -- Diabetes Awareness Month -- The Waylon Fund was Swift's "charity of choice." Half of November's proceeds from thousands of driver donations, as well as matching contributions from Phoenix-based Swift, were collected to benefit TGen's diabetes research in the name of country music legend Waylon Jennings.

In a letter to Swift drivers, Jennings' widow, Jessi Colter, urged them to remember her late husband, who died in 2002 of complications from diabetes, a disease that affects nearly 26 million Americans.

"Waylon Jennings was truly one-of-a-kind. Often thought of as an 'outlaw' and a mentor to a new generation of country and rock acts inspired by his spirit and individualism, he was above all someone who stood strong in the face of adversity," Colter said in her letter. "I am so pleased to announce TGen's new partnership with Jerry Moyes, the founder, chairman and CEO of Phoenix-based Swift Transportation. With the help of Swift Charities and Swift drivers from across the country, The Waylon Fund will spur innovative research at TGen to find better treatments for diabetes."

Jim Stone, Executive Director of Swift Charities, said his company's drivers were eager to answer Colter's call to action.

"Diabetes is one of many health issues that needs greater attention, and we at Swift are proud to partner with another Phoenix-based institution, TGen, to advance biomedical research in this critical area," Stone said. "To be able to do that in conjunction with Jessi Colter, and do it in the memory of Waylon Jennings, that is a real honor."

"TGen's research into diabetes will allow physicians to more accurately predict who has the greatest risk of developing Type 2 diabetes and related complications, while also identifying targets for treatment of the disease," said Dr. Johanna DiStefano, Director of TGen's Diabetes, Cardiovascular & Metabolic Diseases Division.

Dr. DiStefano leads a team of scientists working in five areas of research: diabetes and heart disease, diabetic nephropathy, diabetes and obesity, diabetes and liver disease, and diabetes and individualized treatment strategies.

"TGen is extremely grateful to the Swift Transportation family for supporting The Waylon Fund for Diabetes Research," said Michael Bassoff, President of the TGen Foundation. "This gift from Swift Charities is reflective of the dedication and generosity of Swift employees nationwide who individually contributed to help accelerate TGen's diabetes research."
-end-
For more information about The Waylon Fund, please visit www.thewaylonfund.org.

About TGen

The Translational Genomics Research Institute (TGen) is a Phoenix-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org

The Translational Genomics Research Institute

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.